Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
SRDX's Cash to Debt is ranked higher than
95% of the 298 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.67 vs. SRDX: No Debt )
SRDX' s 10-Year Cash to Debt Range
Min: 50.6   Max: No Debt
Current: No Debt

Equity to Asset 0.94
SRDX's Equity to Asset is ranked higher than
99% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.60 vs. SRDX: 0.94 )
SRDX' s 10-Year Equity to Asset Range
Min: 0.74   Max: 0.96
Current: 0.94

0.74
0.96
Interest Coverage No Debt
SRDX's Interest Coverage is ranked higher than
81% of the 161 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 261.43 vs. SRDX: No Debt )
SRDX' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 8
Z-Score: 38.77
M-Score: -3.15
WACC vs ROIC
12.81%
25.87%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 33.69
SRDX's Operating margin (%) is ranked higher than
99% of the 293 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.36 vs. SRDX: 33.69 )
SRDX' s 10-Year Operating margin (%) Range
Min: -20.11   Max: 51.75
Current: 33.69

-20.11
51.75
Net-margin (%) 21.52
SRDX's Net-margin (%) is ranked higher than
99% of the 293 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.12 vs. SRDX: 21.52 )
SRDX' s 10-Year Net-margin (%) Range
Min: -35.08   Max: 32.59
Current: 21.52

-35.08
32.59
ROE (%) 13.98
SRDX's ROE (%) is ranked higher than
89% of the 281 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.59 vs. SRDX: 13.98 )
SRDX' s 10-Year ROE (%) Range
Min: -12.91   Max: 23.9
Current: 13.98

-12.91
23.9
ROA (%) 13.16
SRDX's ROA (%) is ranked higher than
97% of the 301 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.32 vs. SRDX: 13.16 )
SRDX' s 10-Year ROA (%) Range
Min: -11.85   Max: 19.94
Current: 13.16

-11.85
19.94
ROC (Joel Greenblatt) (%) 105.17
SRDX's ROC (Joel Greenblatt) (%) is ranked higher than
97% of the 300 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.48 vs. SRDX: 105.17 )
SRDX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -18.72   Max: 154.38
Current: 105.17

-18.72
154.38
Revenue Growth (3Y)(%) 11.10
SRDX's Revenue Growth (3Y)(%) is ranked higher than
85% of the 214 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.60 vs. SRDX: 11.10 )
SRDX' s 10-Year Revenue Growth (3Y)(%) Range
Min: -24.6   Max: 57.8
Current: 11.1

-24.6
57.8
EBITDA Growth (3Y)(%) 12.70
SRDX's EBITDA Growth (3Y)(%) is ranked higher than
85% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.30 vs. SRDX: 12.70 )
SRDX' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -32.6   Max: 92.2
Current: 12.7

-32.6
92.2
EPS Growth (3Y)(%) 11.80
SRDX's EPS Growth (3Y)(%) is ranked higher than
86% of the 184 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.60 vs. SRDX: 11.80 )
SRDX' s 10-Year EPS Growth (3Y)(%) Range
Min: -35.4   Max: 46.8
Current: 11.8

-35.4
46.8
» SRDX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

SRDX Guru Trades in Q2 2014

Mario Gabelli 130,778 sh (+292.73%)
Chuck Royce 744,800 sh (+1.57%)
Bill Frels 738,470 sh (-0.14%)
Jim Simons 504,238 sh (-1.21%)
» More
Q3 2014

SRDX Guru Trades in Q3 2014

Mario Gabelli 185,398 sh (+41.77%)
Chuck Royce 744,800 sh (unchged)
Jim Simons 501,938 sh (-0.46%)
Bill Frels 728,390 sh (-1.36%)
» More
Q4 2014

SRDX Guru Trades in Q4 2014

Jim Simons 582,738 sh (+16.10%)
Bill Frels Sold Out
Chuck Royce 718,400 sh (-3.54%)
Chuck Royce 718,400 sh (-3.54%)
Mario Gabelli 120,398 sh (-35.06%)
Bill Frels 40,790 sh (-94.40%)
» More
Q1 2015

SRDX Guru Trades in Q1 2015

Mario Gabelli 117,948 sh (-2.03%)
Chuck Royce 700,800 sh (-2.45%)
Jim Simons 564,838 sh (-3.07%)
Bill Frels 39,440 sh (-3.31%)
» More
» Details

Insider Trades

Latest Guru Trades with SRDX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 27.80
SRDX's P/E(ttm) is ranked higher than
90% of the 338 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. SRDX: 27.80 )
SRDX' s 10-Year P/E(ttm) Range
Min: 8.5   Max: 687.94
Current: 27.8

8.5
687.94
Forward P/E 26.74
SRDX's Forward P/E is ranked higher than
78% of the 338 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. SRDX: 26.74 )
N/A
PE(NRI) 26.30
SRDX's PE(NRI) is ranked higher than
93% of the 338 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. SRDX: 26.30 )
SRDX' s 10-Year PE(NRI) Range
Min: 8.52   Max: 668.29
Current: 26.3

8.52
668.29
P/B 3.80
SRDX's P/B is ranked higher than
66% of the 338 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.79 vs. SRDX: 3.80 )
SRDX' s 10-Year P/B Range
Min: 0.98   Max: 7.77
Current: 3.8

0.98
7.77
P/S 6.02
SRDX's P/S is ranked lower than
52% of the 338 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.40 vs. SRDX: 6.02 )
SRDX' s 10-Year P/S Range
Min: 2.16   Max: 13.8
Current: 6.02

2.16
13.8
PFCF 19.80
SRDX's PFCF is ranked higher than
92% of the 338 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. SRDX: 19.80 )
SRDX' s 10-Year PFCF Range
Min: 8.44   Max: 511.5
Current: 19.8

8.44
511.5
POCF 17.60
SRDX's POCF is ranked higher than
90% of the 338 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. SRDX: 17.60 )
SRDX' s 10-Year POCF Range
Min: 5.96   Max: 36.68
Current: 17.6

5.96
36.68
EV-to-EBIT 14.37
SRDX's EV-to-EBIT is ranked higher than
93% of the 338 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. SRDX: 14.37 )
SRDX' s 10-Year EV-to-EBIT Range
Min: -47.4   Max: 253.6
Current: 14.37

-47.4
253.6
Shiller P/E 159.20
SRDX's Shiller P/E is ranked higher than
75% of the 338 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. SRDX: 159.20 )
SRDX' s 10-Year Shiller P/E Range
Min: 16.9   Max: 165.81
Current: 159.2

16.9
165.81
Current Ratio 16.82
SRDX's Current Ratio is ranked higher than
97% of the 293 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.64 vs. SRDX: 16.82 )
SRDX' s 10-Year Current Ratio Range
Min: 1.57   Max: 18.27
Current: 16.82

1.57
18.27
Quick Ratio 15.92
SRDX's Quick Ratio is ranked higher than
97% of the 293 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.22 vs. SRDX: 15.92 )
SRDX' s 10-Year Quick Ratio Range
Min: 1.49   Max: 18
Current: 15.92

1.49
18
Days Inventory 129.50
SRDX's Days Inventory is ranked higher than
70% of the 338 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 137.36 vs. SRDX: 129.50 )
SRDX' s 10-Year Days Inventory Range
Min: 33.96   Max: 234.64
Current: 129.5

33.96
234.64
Days Sales Outstanding 30.70
SRDX's Days Sales Outstanding is ranked higher than
95% of the 338 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 76.63 vs. SRDX: 30.70 )
SRDX' s 10-Year Days Sales Outstanding Range
Min: 28.08   Max: 80.51
Current: 30.7

28.08
80.51

Valuation & Return

vs
industry
vs
history
Price/Net Cash 7.70
SRDX's Price/Net Cash is ranked higher than
89% of the 338 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. SRDX: 7.70 )
SRDX' s 10-Year Price/Net Cash Range
Min: 3.9   Max: 700
Current: 7.7

3.9
700
Price/Net Current Asset Value 6.90
SRDX's Price/Net Current Asset Value is ranked higher than
88% of the 338 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. SRDX: 6.90 )
SRDX' s 10-Year Price/Net Current Asset Value Range
Min: 3.27   Max: 160.14
Current: 6.9

3.27
160.14
Price/Tangible Book 4.50
SRDX's Price/Tangible Book is ranked higher than
77% of the 338 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.20 vs. SRDX: 4.50 )
SRDX' s 10-Year Price/Tangible Book Range
Min: 1.26   Max: 18.49
Current: 4.5

1.26
18.49
Price/DCF (Projected) 1.70
SRDX's Price/DCF (Projected) is ranked higher than
89% of the 338 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. SRDX: 1.70 )
SRDX' s 10-Year Price/DCF (Projected) Range
Min: 0.53   Max: 4.59
Current: 1.7

0.53
4.59
Price/Median PS Value 1.00
SRDX's Price/Median PS Value is ranked higher than
82% of the 338 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.30 vs. SRDX: 1.00 )
SRDX' s 10-Year Price/Median PS Value Range
Min: 0.4   Max: 7.84
Current: 1

0.4
7.84
Price/Peter Lynch Fair Value 7.30
SRDX's Price/Peter Lynch Fair Value is ranked higher than
86% of the 338 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. SRDX: 7.30 )
SRDX' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.47   Max: 31.8
Current: 7.3

0.47
31.8
Price/Graham Number 2.30
SRDX's Price/Graham Number is ranked higher than
91% of the 338 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. SRDX: 2.30 )
SRDX' s 10-Year Price/Graham Number Range
Min: 0.9   Max: 12.63
Current: 2.3

0.9
12.63
Earnings Yield (Greenblatt) 6.90
SRDX's Earnings Yield (Greenblatt) is ranked higher than
93% of the 298 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.50 vs. SRDX: 6.90 )
SRDX' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.4   Max: 22
Current: 6.9

0.4
22
Forward Rate of Return (Yacktman) 22.26
SRDX's Forward Rate of Return (Yacktman) is ranked higher than
91% of the 114 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.90 vs. SRDX: 22.26 )
SRDX' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 1.1   Max: 52.9
Current: 22.26

1.1
52.9

Analyst Estimate

Sep15 Sep16 Sep17
Revenue(Mil) 59 62 71
EPS($) 0.89 0.97 1.12
EPS without NRI($) 0.89 0.97 1.12

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, ALR, DGX, LIFE, ENZ » details
SurModics Inc was organized as a Minnesota corporation in June 1979. The Company is a provider of surface modification and in vitro diagnostic technologies to the healthcare industry. The Company's core offerings include surface modification coating technologies that impart lubricity, prohealing, and biocompatibility characteristics and components for in vitro diagnostic test kits and specialized surfaces for cell culture and microarrays. It partners with many of the emerging medical device, pharmaceutical and life science companies to develop and commercialize innovative products designed to improve patient outcomes. Although its drug delivery and surface modification technologies themselves are not directly regulated by the Food and Drug Administration, the medical devices, pharmaceutical and biotechnology products incorporating its technologies are subject to FDA regulation.
» More Articles for SRDX

Headlines

Articles On GuruFocus.com
SurModics Inc. Reports Operating Results (10-Q) Aug 06 2010 
SurModics Inc. Reports Operating Results (10-Q) May 07 2010 
SurModics Inc. Reports Operating Results (10-Q) Feb 05 2010 
SurModics Inc. Reports Operating Results (10-K) Dec 11 2009 
SurModics Inc. (SRDX) Senior VP & CFO Philip D Ankeny sells 5,000 Shares Oct 08 2009 
SurModics Inc. Reports Operating Results (10-Q) Aug 07 2009 
SurModics Inc. Reports Operating Results (10-Q) May 08 2009 
SurModics Inc. Reports Operating Results (10-Q) Feb 09 2009 
SurModics Reports First Quarter 2009 Results Jan 28 2009 
SurModics to Webcast Fiscal 2009 First Quarter Earnings Conference Call January 28 Jan 14 2009 

More From Other Websites
SURMODICS INC Financials May 13 2015
10-Q for SurModics, Inc. May 07 2015
SURMODICS INC Files SEC form 10-Q, Quarterly Report May 05 2015
SurModics Misses on Q2 Earnings, Reaffirms 2015 Guidance - Analyst Blog May 01 2015
SurModics Inc Earnings Call scheduled for 5:00 pm ET today Apr 30 2015
SurModics Reports Second Quarter Fiscal 2015 Results Apr 30 2015
SURMODICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Change in Directors... Apr 30 2015
SurModics misses 2Q profit forecasts Apr 30 2015
SurModics misses 2Q profit forecasts Apr 30 2015
SurModics Reports Second Quarter Fiscal 2015 Results Apr 30 2015
Wright Medical Q1 Loss Wider than Expected, Sales Up Y/Y - Analyst Blog Apr 30 2015
Q2 2015 SurModics Inc Earnings Release - After Market Close Apr 30 2015
Healthways Expands on Strategic Collaborations, Eyes Growth - Analyst Blog Apr 29 2015
Chemed Posts Stellar Q1; Beats on Earnings and Revenues - Analyst Blog Apr 29 2015
Boston Scientific Q1 Earnings in Line, '15 Sales View Bleak - Analyst Blog Apr 28 2015
Meridian Bioscience Earnings in Line; Revenues Top in Q2 - Analyst Blog Apr 28 2015
Universal Health Services Beats on Q1 Earnings, Revenues - Analyst Blog Apr 28 2015
Healthways (HWAY) Lags Q1 Earnings, Revenue Estimates - Analyst Blog Apr 24 2015
Accuray's (ARAY) InCise MLC Reaches International Markets - Analyst Blog Apr 23 2015
St. Jude Medical (STJ) Looks Good: Stock Gains 6.4% - Tale of the Tape Apr 23 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK